TY - JOUR
T1 - Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
AU - Thompson, John A.
AU - Schneider, Bryan J.
AU - Brahmer, Julie
AU - Achufusi, Amaka
AU - Armand, Philippe
AU - Berkenstock, Meghan K.
AU - Bhatia, Shailender
AU - Budde, Lihua E.
AU - Chokshi, Saurin
AU - Davies, Marianne
AU - Elshoury, Amro
AU - Gesthalter, Yaron
AU - Hegde, Aparna
AU - Jain, Michael
AU - Kaffenberger, Benjamin H.
AU - Lechner, Melissa G.
AU - Li, Tianhong
AU - Marr, Alissa
AU - McGettigan, Suzanne
AU - McPherson, Jordan
AU - Medina, Theresa
AU - Mohindra, Nisha A.
AU - Olszanski, Anthony J.
AU - Oluwole, Olalekan
AU - Patel, Sandip P.
AU - Patil, Pradnya
AU - Reddy, Sunil
AU - Ryder, Mabel
AU - Santomasso, Bianca
AU - Shofer, Scott
AU - Sosman, Jeffrey A.
AU - Wang, Yinghong
AU - Zaha, Vlad G.
AU - Lyons, Megan
AU - Dwyer, Mary
AU - Hang, Lisa
N1 - Publisher Copyright:
© 2022 Harborside Press. All rights reserved.
PY - 2022/4
Y1 - 2022/4
N2 - The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit NCCN.org.
AB - The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit NCCN.org.
KW - Humans
KW - Immune Checkpoint Inhibitors
KW - Immunologic Factors/therapeutic use
KW - Immunotherapy/adverse effects
KW - Medical Oncology
KW - Neoplasms/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=85129042015&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000790198700009&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2022.0020
DO - 10.6004/jnccn.2022.0020
M3 - Article
C2 - 35390769
SN - 1540-1405
VL - 20
SP - 387
EP - 405
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 4
ER -